Porton Fine Chemicals Ltd (300363) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Porton Fine Chemicals Ltd (300363) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥126.55 Million ≈ $18.52 Million USD) by net assets (CN¥5.49 Billion ≈ $803.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 300363 market cap overview for the company's overall valuation and market capitalisation.
Porton Fine Chemicals Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Porton Fine Chemicals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Porton Fine Chemicals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Porton Fine Chemicals Ltd ranked by their cash flow conversion efficiency. Explore Porton Fine Chemicals Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fibra Terrafina
MX:TERRA13
|
0.027x |
|
Shenzhen Qingyi Photomask Ltd
SHG:688138
|
0.031x |
|
CoCreation Grass Co Ltd
SHG:605099
|
0.002x |
|
Guangzhou Goaland Energy Conservation Tech Co Ltd
SHE:300499
|
0.027x |
|
Soulbrain Co. Ltd
KQ:357780
|
0.047x |
|
Yusys Technologies Co Ltd Class A
SHE:300674
|
0.008x |
|
Harbin Boshi Automation Co Ltd
SHE:002698
|
0.010x |
|
Albany International Corporation
NYSE:AIN
|
0.008x |
Annual Cash Flow Conversion Efficiency for Porton Fine Chemicals Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Porton Fine Chemicals Ltd from 2009 to 2024. View Porton Fine Chemicals Ltd (300363) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.41 Billion ≈ $791.83 Million |
CN¥405.53 Million ≈ $59.34 Million |
0.075x | -27.33% |
| 2023-12-31 | CN¥6.10 Billion ≈ $892.61 Million |
CN¥629.06 Million ≈ $92.05 Million |
0.103x | -73.97% |
| 2022-12-31 | CN¥6.47 Billion ≈ $947.10 Million |
CN¥2.56 Billion ≈ $375.26 Million |
0.396x | +245.42% |
| 2021-12-31 | CN¥4.19 Billion ≈ $612.56 Million |
CN¥480.17 Million ≈ $70.26 Million |
0.115x | -22.83% |
| 2020-12-31 | CN¥3.39 Billion ≈ $496.54 Million |
CN¥504.37 Million ≈ $73.81 Million |
0.149x | +29.63% |
| 2019-12-31 | CN¥3.06 Billion ≈ $448.41 Million |
CN¥351.37 Million ≈ $51.42 Million |
0.115x | +70.75% |
| 2018-12-31 | CN¥2.88 Billion ≈ $421.91 Million |
CN¥193.62 Million ≈ $28.33 Million |
0.067x | -66.38% |
| 2017-12-31 | CN¥1.45 Billion ≈ $212.07 Million |
CN¥289.46 Million ≈ $42.36 Million |
0.200x | -4.09% |
| 2016-12-31 | CN¥1.37 Billion ≈ $200.49 Million |
CN¥285.33 Million ≈ $41.75 Million |
0.208x | +118.72% |
| 2015-12-31 | CN¥1.18 Billion ≈ $172.60 Million |
CN¥112.31 Million ≈ $16.43 Million |
0.095x | -31.71% |
| 2014-12-31 | CN¥874.42 Million ≈ $127.96 Million |
CN¥121.92 Million ≈ $17.84 Million |
0.139x | -47.62% |
| 2013-12-31 | CN¥428.43 Million ≈ $62.69 Million |
CN¥114.05 Million ≈ $16.69 Million |
0.266x | -23.60% |
| 2012-12-31 | CN¥327.76 Million ≈ $47.96 Million |
CN¥114.21 Million ≈ $16.71 Million |
0.348x | +31.02% |
| 2011-12-31 | CN¥246.01 Million ≈ $36.00 Million |
CN¥65.43 Million ≈ $9.57 Million |
0.266x | +21.40% |
| 2010-12-31 | CN¥163.21 Million ≈ $23.88 Million |
CN¥35.75 Million ≈ $5.23 Million |
0.219x | -44.12% |
| 2009-12-31 | CN¥81.60 Million ≈ $11.94 Million |
CN¥31.99 Million ≈ $4.68 Million |
0.392x | -- |
About Porton Fine Chemicals Ltd
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more